Evidence map›Paper›PMID 31714926›Full record

ArticlePloS one2019

Effects of 6-mercaptopurine in pressure overload induced right heart failure.

Julie Birkmose Axelsen, Stine Andersen, Xiao-Qing Sun, Steffen Ringgaard, Janus Adler Hyldebrandt, Kondababu Kurakula, Marie-José Goumans, Frances S de Man, Jens Erik Nielsen-Kudsk, Harm-Jan Bogaard and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Julie Birkmose AxelsenDepartment of Cardiology-Research, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-1221-0115
Stine AndersenDepartment of Cardiology-Research, Aarhus University Hospital, Aarhus, Denmark.
Xiao-Qing SunDepartment of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands.
Steffen RinggaardMR Centre, Aarhus University Hospital, Aarhus, Denmark.
Janus Adler HyldebrandtDepartment of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
Kondababu KurakulaDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Marie-José GoumansDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Frances S de ManDepartment of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands.
Jens Erik Nielsen-KudskDepartment of Cardiology-Research, Aarhus University Hospital, Aarhus, Denmark.
Harm-Jan BogaardDepartment of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands.
Asger AndersenDepartment of Cardiology-Research, Aarhus University Hospital, Aarhus, Denmark.
Aarhus University Hospital · DKAmsterdam UMC Location Vrije Universiteit Amsterdam · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral antineoplastic drugs have been proposed as new compounds for pulmonary arterial hypertension treatment but many have cardiotoxic side effects. The chemotherapeutic agent 6-mercaptopurine may have an effect in treatment of pulmonary arterial hypertension but at the same time, its effects on the afterload adaption of the right ventricle is unpredictable due to interaction with multiple downstream signalling pathways in the cardiomyocytes. We investigated the direct cardiac effects of 6-mercaptopurine in rats with isolated right heart failure caused by pulmonary trunk banding (PTB).

methodsMale Wistar rat weanlings (112±2 g) were randomized to sham operation (sham, n = 10) or PTB. The PTB animals were randomized to placebo (PTB-control, n = 10) and 6-mercaptopurine (7.5 mg/kg/day) groups with treatment start before the PTB procedure (PTB-prevention, n = 10) or two weeks after (PTB-reversal, n = 10). Right ventricular effects were evaluated by echocardiography, cardiac MRI, invasive pressure-volume measurements, and histological and molecular analyses.

resultsPTB increased right ventricular afterload and caused right ventricular hypertrophy and failure. 6-mercaptopurine did not improve right ventricular function nor reduce right ventricular remodelling in both prevention and reversal studies compared with placebo-treated rats.

conclusionTreatment with 6-mercaptopurine did not have any beneficial or detrimental effects on right ventricular function or remodelling. Our data suggest that treatment of pulmonary arterial hypertension with 6-mercaptopurine is not harmful to the failing right ventricle.

Indexed as

AnimalsApoptosisBlood PressureDisease Models, AnimalHeart FailureHeart VentriclesHemodynamicsHypertension, PulmonaryMaleMercaptopurineRats, WistarVentricular Function, RightVentricular RemodelingMercaptopurine

Identifiers

PMID31714926
PMCPMC6850541
OpenAlexW2987911635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.